| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5552394 | APIL | Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy |
Jul, 2014
(9 years ago) | |
| US6667050 | APIL | Chewable oral contraceptive |
Apr, 2019
(5 years ago) | |
Minastrin 24 Fe is owned by Apil.
Minastrin 24 Fe contains Ethinyl Estradiol; Norethindrone Acetate.
Minastrin 24 Fe has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Minastrin 24 Fe are:
- US5552394
- US6667050
Minastrin 24 Fe was authorised for market use on 08 May, 2013.
Minastrin 24 Fe is available in tablet;oral dosage forms.
Minastrin 24 Fe can be used as prevention of pregnancy.
The generics of Minastrin 24 Fe are possible to be released after 06 April, 2019.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | May 08, 2016 |
Drugs and Companies using ETHINYL ESTRADIOL; NORETHINDRONE ACETATE ingredient
Market Authorisation Date: 08 May, 2013
Treatment: Prevention of pregnancy
Dosage: TABLET;ORAL
How can I launch a generic of MINASTRIN 24 FE before it's drug patent expiration?
More Information on Dosage
MINASTRIN 24 FE family patents
